Akanda (AKAN) Competitors $0.77 +0.02 (+2.67%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends AKAN vs. IGNY, BLPH, NEXI, SEEL, SMFL, BDRX, PRFX, SXTC, TCON, and VAXXShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Ignyte Acquisition (IGNY), Bellerophon Therapeutics (BLPH), NexImmune (NEXI), Seelos Therapeutics (SEEL), Smart for Life (SMFL), Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), China SXT Pharmaceuticals (SXTC), TRACON Pharmaceuticals (TCON), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Ignyte Acquisition Bellerophon Therapeutics NexImmune Seelos Therapeutics Smart for Life Biodexa Pharmaceuticals PainReform China SXT Pharmaceuticals TRACON Pharmaceuticals Vaxxinity Akanda (NASDAQ:AKAN) and Ignyte Acquisition (NASDAQ:IGNY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends. Do analysts recommend AKAN or IGNY? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AIgnyte Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more volatility & risk, AKAN or IGNY? Akanda has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Ignyte Acquisition has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Is AKAN or IGNY more profitable? Ignyte Acquisition's return on equity of 365.46% beat Akanda's return on equity.Company Net Margins Return on Equity Return on Assets AkandaN/A N/A N/A Ignyte Acquisition N/A 365.46%-0.83% Do institutionals and insiders hold more shares of AKAN or IGNY? 1.0% of Akanda shares are held by institutional investors. Comparatively, 61.1% of Ignyte Acquisition shares are held by institutional investors. 20.4% of Akanda shares are held by insiders. Comparatively, 19.9% of Ignyte Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in AKAN or IGNY? Akanda and Ignyte Acquisition both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformAkandaN/AN/AIgnyte AcquisitionN/AN/A Which has preferable earnings and valuation, AKAN or IGNY? Ignyte Acquisition has lower revenue, but higher earnings than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkanda$2.51M0.88-$32.28MN/AN/AIgnyte AcquisitionN/AN/A-$490KN/AN/A Does the media refer more to AKAN or IGNY? In the previous week, Akanda's average media sentiment score of 0.56 beat Ignyte Acquisition's score of 0.00 indicating that Akanda is being referred to more favorably in the media. Company Overall Sentiment Akanda Positive Ignyte Acquisition Neutral SummaryAkanda beats Ignyte Acquisition on 5 of the 8 factors compared between the two stocks. Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.20M$1.24B$5.04B$8.43BDividend YieldN/AN/A7.52%4.16%P/E RatioN/A39.08130.2316.67Price / Sales0.888.691,720.2276.26Price / CashN/A15.5336.9133.54Price / Book-0.022.094.604.98Net Income-$32.28M-$50.21M$114.94M$224.26M7 Day Performance-9.37%-0.28%0.14%1.65%1 Month Performance-28.08%12.89%10.15%6.92%1 Year Performance-95.73%9.44%33.87%26.46% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$0.77+2.7%N/A-95.8%$2.20M$2.51M0.00110IGNYIgnyte AcquisitionN/A$0.07flatN/AN/A$510,000.00N/A0.003BLPHBellerophon Therapeutics0.3633 of 5 stars$0.04flatN/A-7.7%$440,000.00$5.64M-0.0420NEXINexImmuneN/A$0.27flatN/A-92.5%$371,000.00N/A-0.0170SEELSeelos TherapeuticsN/A$0.99-22.0%N/A-99.9%$368,000.00$2.20M0.0020SMFLSmart for LifeN/A$0.05flatN/A-99.8%$354,000.00$8.23M0.00110BDRXBiodexa Pharmaceuticals1.9553 of 5 stars$6.66+2.3%$200.00+2,903.0%N/A$333,000.00$470,000.000.0021Gap DownPRFXPainReform1.7648 of 5 stars$0.56-6.7%$2.00+257.1%-80.9%$324,000.00N/A-0.024SXTCChina SXT Pharmaceuticals0.2489 of 5 stars$0.61+3.4%N/A-77.1%$280,000.00$1.93M0.0090News CoverageTCONTRACON Pharmaceuticals1.4047 of 5 stars$0.08+13.9%$60.00+73,070.7%-98.2%$273,000.00$12.15M0.0220Gap UpVAXXVaxxinityN/A$0.00flatN/A-99.8%$254,000.00$70,000.000.0090Gap Up Related Companies and Tools Related Companies IGNY Competitors BLPH Competitors NEXI Competitors SEEL Competitors SMFL Competitors BDRX Competitors PRFX Competitors SXTC Competitors TCON Competitors VAXX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKAN) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKAN Stock Alerts